Apellis Pharmaceuticals Highlights Upcoming Investor Events

Author: Olivia Taylor Updated: 08-27-2025 07:17 AM

Apellis Pharmaceuticals Engaging with Investors

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a leading biotech innovator, is gearing up for an exciting series of investor conferences. These events are designed to share insights about their groundbreaking advancements in complement science and how they plan to transform treatment for serious diseases. As a forward-thinking biopharmaceutical company, Apellis is committed to developing therapies that can bring real change to patients’ lives.

Key Upcoming Conferences

During this important time, Apellis will be participating in several key investor conferences that provide a platform for their management to present and engage with diverse investor audiences. These conferences include:

Wells Fargo Healthcare Conference

This event is scheduled for Wednesday, September 3, and will kick off at 8:45 a.m. ET. It is an excellent opportunity for investors to learn about the company’s strategy and future roadmap directly from its leadership.

Cantor Global Healthcare Conference

Following closely, Apellis will take part in the Cantor Global Healthcare Conference on Thursday, September 4, starting at 8:35 a.m. ET. This conference will allow Apellis to showcase their innovative solutions to health challenges faced by patients.

Baird Global Healthcare Conference

On Tuesday, September 9, at 10:15 a.m. ET, Apellis will present at the Baird Global Healthcare Conference. These presentations are crucial for connecting with investors who are eager to learn more about the potential impact of their therapies.

Interactive Conference Experience

For those who are unable to attend the conferences, Apellis ensures that the live webcasts of their presentations will be accessible via the “Events and Presentations” section on their website. Typically, a recorded replay of these sessions will be available for about 30 days post-event, allowing investors the flexibility to catch up on any missed information.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals is at the forefront of complement science, having introduced the first new class of complement medicine in over a decade. Their dedicated research and development efforts have resulted in two C3-targeting therapies currently approved for various serious conditions, including geographic atrophy, a leading cause of blindness, and severe kidney diseases like C3G and primary IC-MPGN.

Their dedication to innovation extends beyond existing products, as Apellis actively seeks to explore the vast potential of C3-targeted therapies across numerous serious health issues.

Investor Relations

For inquiries or further information, interested individuals can reach out to Apellis Pharmaceuticals' Investor Contact:

Eva Stroynowski

Email: eva.stroynowski@apellis.com
Phone: 617.938.6229

Frequently Asked Questions

What is Apellis Pharmaceuticals known for?

Apellis Pharmaceuticals is known for its pioneering work in complement science and developing therapies for serious diseases, including eye and kidney conditions.

When are the upcoming investor conferences?

The conferences are scheduled for September 3, 4, and 9, with specific times for each event.

How can investors access the conference webcasts?

Investors can access the live webcasts through the “Events and Presentations” section on Apellis' website, with replays available for 30 days.

What types of therapies does Apellis offer?

Apellis offers C3-targeting therapies that treat diseases such as geographic atrophy and severe kidney diseases, with ongoing research into additional applications.

Who can be contacted for investor inquiries?

Investor inquiries can be directed to Eva Stroynowski at Apellis Pharmaceuticals via email or phone.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.